Supply Chain Challenges For Cell & Gene

Cell and Gene therapies are enabling treatment for a number of diseases which previously had little to no therapeutic products available. However, the highly customized associated processes and the lack of standardized supply chain specifications often lead to extended timelines and high costs for patients.

Maggie Chen, Senior Director, Manufacturing & MSAT, AGC Biologics, discusses how reducing the supply chain complexity and introducing automation will help to benefit patients and the industry as a whole.